First clinical experiences with inclisiran in real world setting

Back

ESC Professional Premium Access

First clinical experiences with inclisiran in real world setting

Session: PCSK9 inhibitors and inclisiran

Topic: Lipid-Lowering Agents

Speaker: Doctor A. Galema-Boers (Rotterdam, NL)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Annette Galema-Boers

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

0 follower

8 more presentations in this session

Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)

Speaker: Doctor C. Basile (Naples, IT)

Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials

Speaker: Ms J. Grover (Sydney, AU)

Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands

Speaker: Doctor Q. Chan (Greater London, GB)

The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study

Speaker: Mr J. Kraaijenhof (Amsterdam, NL)

Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins

Speaker: Associate Professor R. Santos (Sao Paulo, BR)

Access the full session

PCSK9 inhibitors and inclisiran

Speakers: Doctor A. Galema-Boers, Doctor C. Basile, Ms J. Grover, Doctor Q. Chan, Mr J. Kraaijenhof...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

First clinical experiences with inclisiran in real world setting

About the speaker

Doctor Annette Galema-Boers

8 more presentations in this session

Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)

Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials

Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands

The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study

Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins

Access the full session

PCSK9 inhibitors and inclisiran

About the event

ESC Congress 2023

ESC 365 is supported by